GlassScriptPhysician profile
Rachel L Case
NPI 1104011592
$6,254.84
in general payments reported to CMS, 2019-2025
32 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $629 · 2022: $1,499 · 2023: $1,607 · 2024: $1,399 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,126.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $872.12 | 2021-2025 | |
| Abbott Laboratories | $630.04 | 2021-2025 | Cardiomems, Gallant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $603.88 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $540.50 | 2022-2025 | Farxiga, Wainua, Andexxa |
| Merck Sharp & Dohme LLC | $451.80 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $337.88 | 2021-2025 | Camzyos, Eliquis |
| Philips North America LLC | $320.45 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Boston Scientific Corporation | $292.56 | 2021-2025 | Watchman Access System, Watchman Flx, Cds - Mct/Cem Monitoring |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $282.90 | 2021-2025 | Lifevest |
| Pfizer INC. | $239.60 | 2021-2025 | |
| Amgen INC. | $194.48 | 2021-2025 | Repatha, Repatha |
| Atricure, INC. | $186.48 | 2023 | |
| Daiichi Sankyo INC. | $159.47 | 2021-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $149.42 | 2022-2024 | |
| Novo Nordisk INC | $117.02 | 2024-2025 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $115.23 | 2024-2025 | Impella |
| Impulse Dynamics (USA) INC. | $113.30 | 2021-2025 | Optimizer |
| Cvrx, INC. | $105.67 | 2023-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $78.58 | 2022-2024 | Onpattro |
| Janssen Pharmaceuticals, INC | $59.84 | 2023-2024 | Xarelto |
| Vital Connect, INC | $56.93 | 2023-2025 | Vitalpatch Rtm |
| Sanofi-Aventis U.S. LLC | $55.89 | 2022-2023 | |
| Scpharmaceuticals INC. | $54.28 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $40.17 | 2023 | Arcalyst |
| Irhythm Technologies, INC. | $33.74 | 2024 | Zio Monitor, Zio Xt Patch |
| Medtronic, INC. | $33.42 | 2022 | |
| Kestra Medical Technology Services, INC. | $30.36 | 2025 | Assure Wcd |
| Recor Medical INC | $25.48 | 2024 | Paradise Renal Denervation System |
| Actelion Pharmaceuticals US, INC. | $23.68 | 2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $20.27 | 2024 | |
| Glaxosmithkline, LLC. | $18.38 | 2023 | Shingrix |
| Daxor Corporation | $11.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.